Miyamoto and colleagues present data that prostate-specific antigen/prostate-specific membrane antigen (PSA/PSMA)-based measurements of androgen receptor (AR) signaling in circulating tumor cells (CTC) enable real-time quantitative monitoring of intratumoral AR signaling.
This finding indicates that measuring AR signaling within CTCs may help to guide therapy in metastatic prostate cancer and highlights the use of CTCs as liquid biopsy.
Written by:
Pantel K, Alix-Panabières C. Are you the author?
Department of Tumour Biology, Centre of Experimental Medicine, University Cancer Center Hamburg, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; Laboratory of Rare Human Circulating Cells, Institute of Research in Biotherapy, University Medical Centre, University Montpellier 1, Saint-Eloi Hospital; Laboratory of Cell and Hormonal Biology, University Medical Centre, Arnaud de Villeneuve Hospital; and University Institute of Clinical Research UM1-EA2415-Epidemiology, Biostatistics and Public Health, Montpellier, France.
Reference: Cancer Discov. 2012 Nov;2(11):974-975.
doi: 10.1158/2159-8290.CD-12-0432
PubMed Abstract
PMID: 23093252
UroToday.com Prostate Cancer Section
